Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

ones and receipt of milestone payments from Shire. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G

     Table 1
                            Amicus Therapeutics, Inc.
                          (a development stage company)
                      Consolidated Statements of Operations
                                   (Unaudited)
                (In thousands, except share and per share amounts)


                                                                   Period from
                                                                   February 4,
                                                                       2002
                                                                   (inception)
                              Three Months          Six Months          to
                             Ended June 30,        Ended June 30,    June 30,
                             2008      2009        2008      2009      2009

    Revenue:
      Research revenue     $3,113     $4,667     $5,579     $8,580   $22,143
      Collaboration
       revenue                694        694      1,389      1,389     4,576
    Total revenue           3,807      5,361      6,968      9,969    26,719

    Operating Expenses:
      Research and
       development         
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 Biotech ... development of emerging drug systems and advanced Laboratory Instrumentation. ... and Company (NYSE: BDX ), Thermo Fisher ... Inc. (NASDAQ: RGDO ), Sangamo Biosciences Inc. ... HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ...
(Date:9/19/2014)... St. Paul, Minnesota (PRWEB) September 19, 2014 ... representatives from related food industries will gather October ... Meeting at the Rhode Island Convention Center in ... exhibition will feature the work of food scientists, ... development, quality control, and food production management. To ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
Breaking Biology Technology:Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... Therapeutics, Inc., a,privately held biopharmaceutical company, announced today ... will present a corporate,overview at the JMP Securities ... 7 at 9 a.m. ET at the Le ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company,focused ...
... 1 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix, today announced that it will,host a ... 12:15 p.m. EDT. A,webcast of the presentations will ... PRESENTATIONS, -- Strategic Company Overview, Jonathan Lim, ...
... - OncoGenex,Pharmaceuticals, Inc (NASDAQ: OGXI ) will ... on October 2 at 4:30 pm ET in ... City. OncoGenex, President and,Chief Executive Officer, Scott Cormack, ... a discussion of the Company,s lead cancer drug,candidate ...
Cached Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... were instrumental in the creation of the Santa Ana ... the fire threat potential of the powerful, hot, dry ... an inferno. The index was introduced Sept. 17 by ... San Diego Gas and Electric. , The index includes ... will be used to help fire agencies and other ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (UW) researchers have gathered evidence that dangerous plaques in ... are fat-laden rough spots in the otherwise smooth walls ... of it, a process known as plaque hemorrhage. The ... flow of oxygen-rich blood is restricted, a heart attack, ...
... A Brazilian scorpion has provided researchers at North ... venom,s effects on the ability of certain cells to ... understanding diseases like pancreatitis or in targeted drug delivery. ... an inflammation of the pancreas. ECU microbiologist Dr. Paul ...
... Science Foundation has bestowed a Faculty Early Career Development ... molecular biologist and geneticist whose work since she joined ... her passion for research and her commitment to training ... Award is an exceptional recognition of exceptional qualities in ...
Cached Biology News:Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 2Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 3Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 4Scorpion venom provides clues to cause, treatment of pancreatitis 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: